摘要
目的探讨聚乙二醇a-2b干扰素(PEG-IFNa-2b)治疗丙型肝炎的临床疗效。方法选取徐州市传染病医院2014年9月—2016年7月收治的丙型肝炎患者120例,随机分为PEG-IFNa-2b组和干扰素a-2b(IFNa-2b)组,每组60例。PEG-IFNa-2b组患者给予PEG-IFNa-2b联合利巴韦林治疗,IFNa-2b组患者给予IFNa-2b联合利巴韦林治疗,两组患者均持续治疗48周。比较两组患者抗病毒治疗效果与高、低病毒载量获得率。结果PEG-IFNa-2b组患者快速病毒学应答(RVR)、早期病毒学应答(EVR)及持续病毒学应答(SVR)获得率高于IFNa-2b组(P<0.05)。在高病毒载量上,PEG-IFNa-2b组患者EVR、SVR、RVR获得率高于IFNa-2b组(P<0.05)。两组患者低病毒载量获得率比较,差异无统计学意义(P>0.05)。结论 PEG-IFNa-2b治疗丙型肝炎的临床疗效确切,尤其在高病毒载量患者中借鉴意义更大。
Objective To investigate the clinical effect of PEG-IFNa-2b on hepatitis C. Methods A total of 120 cases of patients with hepatitis C were selected from September 2014 to July 2016 in Xuzhou Infectious Disease Hospital,which were randomly divided into PEG-IFNa-2b group and IFNa-2b group,60 cases in each group. PEG-IFNa-2b group was given PEG-IFNa-2b combined with ribavirin,IFNa-2b group was given IFNa-2b combined with ribavirin,both groups were treated for 48 weeks. The treatment outcome,and the received rate of high and low viral load were compared between the two groups. Results The PEG-IFNa-2b group of received rate of RVR,EVR,SVR were higher than IFNa-2b group（ P 〈0. 05）. In high viral load,the PEG-IFNa-2b group of received rate of RVR,EVR,SVR were higher than IFNa-2b group（ P 〈0. 05）. In low viral load,no siginificant differences of received rate of RVR,EVR,SVR was found between the two groups（ P 〉0. 05）. Conclusion PEG-IFNa-2b has an exactly clinical effect in treating hepatitis C,especially in patients with high viral load.
出处
《临床合理用药杂志》
2017年第27期11-12,共2页
Chinese Journal of Clinical Rational Drug Use
